Trinity Biotech
TRIB
21 hedge funds and large institutions have $7.5M invested in Trinity Biotech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
40% more call options, than puts
Call options by funds: $21K | Put options by funds: $15K
5% more funds holding
Funds holding: 20 → 21 (+1)
0.04% less ownership
Funds ownership: 0.96% → 0.92% (-0.04%)
16% less capital invested
Capital invested by funds: $8.92M → $7.5M (-$1.43M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$18.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.2K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.08K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$261K |
| 2 |
Renaissance Technologies
New York
|
-$83.9K |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$14.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$14K |
| 5 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$11.8K |
TRIB Hedge Fund Activity: Q3 2022 in Review
21 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2022, worth a combined $7.5M — down 16% from $8.92M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TRIB positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $18.9K. The largest seller was Stonehill Capital Management, cutting an estimated $261K.
- 21 institutional investors held Trinity Biotech (TRIB) as of Q3 2022, up from 20 in Q2 2022.
- Funds reported $7.5M of Trinity Biotech stock for Q3 2022, down 16% quarter-over-quarter.
- 2 funds opened new Trinity Biotech positions in Q3 2022 and 1 closed out, a net change of +1 holder.
- The largest Trinity Biotech buyer in Q3 2022 was Virtu Financial, an estimated $18.9K added.
- The largest Trinity Biotech seller in Q3 2022 was Stonehill Capital Management, an estimated $261K sold.
Based on aggregated 13F filings for Q3 2022.